Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Core Insights - Axogen, Inc. reported strong preliminary financial results for the fourth quarter and full year of 2025, highlighting significant revenue growth and a key milestone with the approval of Avance as a biologic therapeutic option for peripheral nerve treatment [3][7]. Financial Performance - Fourth quarter 2025 revenue is expected to be approximately $59.9 million, reflecting a 21.3% increase compared to the fourth quarter of 2024 [7]. - Full-year 2025 revenue is projected to be around $225.2 million, representing a 20.2% increase over the full year of 2024 [7]. - Gross margin for both the fourth quarter and full year of 2025 is anticipated to be above 74%, with one-time costs related to the FDA BLA approval of Avance impacting margins [7]. Strategic Developments - The company is focusing on improving execution across its commercial strategy, targeting high-potential accounts in Extremities and OMF-Head & Neck, and expanding the utilization of its complete peripheral nerve surgical algorithm [7]. - The approval of Avance is seen as a validation of the company's strategic plan and market development efforts, reinforcing its mission to make peripheral nerve function restoration a standard of care [3][7]. Cash Position - As of December 31, 2025, the balance of cash, cash equivalents, restricted cash, and investments is expected to be approximately $45.5 million, an increase of about $6.0 million from the end of 2024 [7].